ArticleJournal of neuro-oncology2026
Differential expression of TGF-β1, TGF-β2, and TGF-β3 across WHO grades in meningioma: convergent evidence from mRNA, methylation, miRNA, and protein analysis.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMeningiomas show biological heterogeneity not captured by WHO grading alone. TGF-β signaling has been implicated in meningioma pathobiology, yet a systematic, grade-stratified, isoform-resolved characterization of TGF-β1, TGF-β2, and TGF-β3 across transcriptional, epigenetic, post-transcriptional, and protein levels had not been performed.
methodsWe prospectively enrolled 154 patients undergoing resection of WHO CNS5 grade 1 meningothelial (n = 124) or grade 2 atypical (n = 30) meningioma across two neurosurgical centers. TGF-β1-3 mRNA and six bioinformatically prioritized targeting microRNAs were quantified by RT-qPCR; promoter methylation was assessed by methylation-specific PCR; protein abundance was measured by ELISA, Western blotting, and immunohistochemistry.
resultsTGF-β2 and TGF-β3 mRNA were markedly upregulated in grade 2 (fold-change 5.68 and 5.23, respectively), corroborated by higher ELISA and IHC signal, though not by Western blot. TGF-β1 mRNA expression was markedly reduced in grade 2 (fold-change 0.039) with reduced protein, despite a predominantly unmethylated promoter (76.7% unmethylated). Nearly all grade 1 specimens showed hypermethylated TGF-β1-3 promoters (95-97%), whereas most grade 2 specimens showed an unmethylated promoter (73-77%). All six candidate microRNAs, notably miR-200a-3p/miR-141-3p, were coordinately downregulated in grade 2.
conclusionThese findings show a grade-dependent, isoform-specific pattern of TGF-β dysregulation in meningioma: transcriptional, epigenetic, and post-transcriptional signals converge at the TGF-β2/TGF-β3 axis, alongside a paradoxical reduction in TGF-β1 mRNA that methylation status alone does not explain. This profile nominates TGF-β2/TGF-β3 and the miR-200 family as candidate biomarkers in atypical meningioma, while identifying TGF-β1 regulation as a distinct question for functional follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.